Smith & Nephew (LON:SN) Receives “Buy” Rating from Jefferies Financial Group

Smith & Nephew (LON:SN)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a note issued to investors on Thursday,Digital Look reports. They currently have a GBX 2,760 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 141.05% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Royal Bank Of Canada lowered shares of Smith & Nephew to a “sector perform” rating and set a GBX 1,350 target price on the stock. in a report on Thursday, May 7th. Berenberg Bank restated a “hold” rating and issued a GBX 13 price objective on shares of Smith & Nephew in a research report on Friday, May 1st. Finally, UBS Group reaffirmed a “neutral” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of GBX 1,382.63.

Smith & Nephew Price Performance

Smith & Nephew stock opened at GBX 1,145 on Thursday. The company has a market cap of £12.55 billion, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 0.46 and a beta of 0.67. The business’s fifty day moving average price is GBX 1,191.01 and its 200 day moving average price is GBX 1,239.83. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.